- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00872378
The Effects of Exenatide After Gastric Restriction (AGREE)
March 30, 2009 updated by: Advanced Specialty Care
A Pilot Study of the Effects of BYETTA® (Exenatide) on Weight Loss in Morbidly Obese Non Diabetic Patients Following Adjustable Gastric Banding
The purpose of this study is to describe change in body weight in non-diabetic morbidly obese patients after laparoscopic adjustable gastric banding (LAGB) with twice daily exenatide or placebo injections.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
28
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Megan E Boone, BS
- Phone Number: 541-322-1772
- Email: megan@advancedspecialtycare.com
Study Locations
-
-
Oregon
-
Bend, Oregon, United States, 97701
- Recruiting
- Advanced Specialty Care
-
Contact:
- Megan E Boone, BS
- Phone Number: 541-322-1772
- Email: megan@advancedspecialtycare.com
-
Sub-Investigator:
- Ngocthuy Hughes, MD
-
Sub-Investigator:
- Stephen B Archer, MD FACS
-
Bend, Oregon, United States, 97701
- Recruiting
- Endocrinology Services NorthWest
-
Contact:
- Megan E Boone, BS
- Phone Number: 541-322-1772
- Email: megan@advancedspecialtycare.com
-
Principal Investigator:
- Patrick J McCarthy, MD
-
Sub-Investigator:
- Travis L Monchamp, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥ 18 years,
- Have a body mass index ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities (1991 NIH Guidelines for Bariatric Surgery),
- For women of childbearing age, must have a negative pregnancy test at screening, and agree to use barrier contraceptives for the duration of the study, AND
- Are able to understand and comply with the study process, and give informed consent.
Exclusion Criteria:
- A diagnosis of type 1 diabetes mellitus,
- A diagnosis of type 2 diabetes mellitus (A diagnosis of T2DM will be a previous fasting plasma glucose greater than or equal to 126 mg/dL, or a random plasma glucose greater than 200 mg/dL),
- Have experienced hypersensitivity reaction or a worsening of glycemic control on Byetta® (exenatide),
- Patients with end stage renal disease or severe renal impairment,
- Patients with severe gastrointestinal disease, including gastroparesis,
- Liver function tests 2.5 standard deviations above normal values,
- Contraindication for bariatric surgery,
- Treatment with exenatide (Byetta) in the last three months,
- Currently using or have used within three months before this trial: sibutramine, orlistat, or phentermine(patients must also agree to not use these medications for the duration of the study),
- Treatment with any investigational drug in the last 30 days,
- Active malignancy, liver of kidney failure, symptomatic coronary heart disease, or severe psychiatric disease,
- History of malignancy other than basal cell skin carcinoma, OR
- In the opinion of the investigator, patient is abusing alcohol and/or drugs.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Exenatide
Laparoscopic adjustable gastric banding group: twice daily exenatide therapy plus a standard diet and exercise program
|
Exenatide titrated up to 20mcg BID.
(4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
Other Names:
|
Placebo Comparator: Placebo
Laparoscopic adjustable gastric banding group: twice daily placebo therapy plus a standard diet and exercise program
|
Placebo titrated up to 20mcg BID.
(4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To describe change in body weight in non-diabetic morbidly obese patients after laparoscopic adjustable gastric banding (LAGB) with twice daily exenatide plus lifestyle modification plan or placebo plus lifestyle modification plan.
Time Frame: 52 weeks
|
52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Body Mass Index (BMI)
Time Frame: 52 Weeks
|
52 Weeks
|
Waist circumference
Time Frame: 52 Weeks
|
52 Weeks
|
Changes in: 2 hour Oral Glucose Tolerance Test; Lipid panel; Comprehensive metabolic panel; Glycosylated hemoglobin A1c
Time Frame: 52 Weeks
|
52 Weeks
|
Carotid intima media thickness(CIMT)
Time Frame: 52 Weeks
|
52 Weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Patrick J McCarthy, M.D., Endocrinology Services NorthWest
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2009
Primary Completion (Anticipated)
December 1, 2010
Study Completion (Anticipated)
December 1, 2010
Study Registration Dates
First Submitted
March 27, 2009
First Submitted That Met QC Criteria
March 30, 2009
First Posted (Estimate)
March 31, 2009
Study Record Updates
Last Update Posted (Estimate)
March 31, 2009
Last Update Submitted That Met QC Criteria
March 30, 2009
Last Verified
March 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ASC-AGREE Study
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Morbid Obesity
-
ClinTrio Ltd.UnknownMorbid Obesity Requiring Bariatric SurgeryBelgium, Germany, Portugal, Austria, Netherlands, Poland, Saudi Arabia
-
Centre Hospitalier Universitaire de NiceCompletedMorbid Obesity D009765France
-
Shanghai Jiao Tong University School of MedicineUnknown
-
Hospices Civils de LyonCentre de Recherche en Nutrition Humaine Rhone-Alpe; Institut National de Recherche... and other collaboratorsRecruiting
-
Endolumik, IncWest Virginia UniversityNot yet recruitingMorbid ObesityUnited States
-
Rijnstate HospitalRecruiting
-
Laval UniversityCentre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie...Recruiting
-
University of WashingtonUnited States Department of DefenseWithdrawn
-
Helsinki University Central HospitalActive, not recruiting
-
IHU StrasbourgWithdrawnMorbid Obesity
Clinical Trials on Exenatide
-
AstraZenecaEli Lilly and CompanyCompletedType 2 Diabetes MellitusUnited States
-
AstraZenecaCompletedType 2 Diabetes MellitusCanada, United States
-
AstraZenecaEli Lilly and CompanyCompletedType 2 Diabetes MellitusKorea, Republic of, China, Japan, Taiwan, India
-
AstraZenecaEli Lilly and CompanyCompletedType 2 Diabetes MellitusKorea, Republic of, Mexico, Germany, Greece, Argentina, India, Australia
-
AstraZenecaEli Lilly and CompanyCompletedType 2 Diabetes MellitusUnited States
-
AstraZenecaCompletedDiabetes Mellitus, Type 2United States
-
Beijing Chao Yang HospitalCompleted
-
AstraZenecaCelerionCompleted
-
AstraZenecaEli Lilly and CompanyCompletedType 2 DiabetesUnited States
-
Vivani Medical, IncMedpace, Inc.Not yet recruiting